Meta-analysis · people

Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

Across 23 head-to-head trials, teriparatide beat bisphosphonates on fracture risk and bone density in people not previously on a bisphosphonate, without more adverse events.

Kind
Meta-analysis
Studied in
People
Number studied
6680
Published
2024
Journal
Arch Osteoporos

What they tested

The team set out to compare how well and how safely teriparatide and denosumab work against bisphosphonates in people with osteoporosis who had never taken a bisphosphonate.

How the study was done

A systematic review and meta-analysis, which pools results from many studies, of 23 head-to-head randomized controlled trials with 6680 patients in total. Each trial compared teriparatide or denosumab directly with a bisphosphonate.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Teriparatide lowered the risk of fracture compared with bisphosphonates, with a risk ratio (RR, how the risk in one group compares with the other) of 0.61 (95% CI 0.51 to 0.74, P < 0.001). Denosumab did not lower fracture risk compared with bisphosphonates (RR 0.99, 95% CI 0.62 to 1.57, P = 0.96). Both teriparatide and denosumab raised bone mineral density, a measure of how dense the bone is, at the femoral neck, total hip and lumbar spine more than bisphosphonates did (P < 0.05). Neither raised the rate of adverse events: teriparatide RR 0.92 (P = 0.32) and denosumab RR 0.98 (P = 0.37).

What it doesn’t show

The pooled trials differed from each other clinically, so the team used both fixed-effect and random-effect models. It covers only people who had not had a bisphosphonate before, so it doesn't speak to people switching from one.

The paper

Li et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo